glp-1 health Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity These statements have not been evaluated by the Food and Drug Administration GLP-1 and Microbiome Repair for

Beneficiaries with Part D benefits can qualify for discounted GLP-1 coverage by meeting one of the following requirements: Group 1 : Overweight individuals with a Body Mass Index (BMI) greater than 27, individuals with prediabetes or have had a heart attack, stroke or blocked arteries in your legs or arms Group 2 : Overweight individuals with a BMI greater than 30, individuals with certain types of heart failure, high blood pressure thats hard to control, or chronic kidney disease (stage 3a or above) Group 3 : Overweight individuals with a BMI greater than 35

In these plots, the left side indicated a favorable outcome for tirzepatide, while the right side favored the control group(s) [21]

doi: 10.1016/j.mvr.2012.06.008 83 FujitaHMoriiTFujishimaHSatoTShimizuTHosobaMet al

Pontes-da-Silva et al